Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Status:
RECRUITING
Trial end date:
2028-07-30
Target enrollment:
Participant gender:
Summary
To prospectively evaluate the efficacy and safety of large fraction radiation therapy combined with granulocyte-macrophage colony-stimulating factor, lenalidomide, and glofitamab monoclonal antibody in the treatment of refractory relapsed diffuse large B-cell lymphoma patients
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University